Shares in pharmaceutical group Elan slumped to 5 year lows today as investors continue to shun the troubled company.
In Dublin Elan closed down over 10% at 12 euro, whilst in New York it was down nearly 5% at $10.62 at 6pm.
The company has lost more than 70% of its value since the start of the year rocked by accounting concerns and the abandonment of an Alzheimer drug trial.
Goodbody analyst Ian Hunter said that a lack of positive newsflow was hurting Elan, which is due to report first quarter results at the end of the month.
